MetaVia (MTVA) investor relations material

Strategic vision and market positioning

• Focused on developing therapies for obesity and MASH, targeting highly competitive and rapidly evolving markets with anticipated drug launches around 2030–2032.

• Early clinical data for both assets show promising efficacy and safety, differentiating from competitors with failed trials.

• Plans to partner with larger pharmaceutical companies to maximize market potential and navigate competitive landscapes.

• Actively engaged in discussions with big pharma and key opinion leaders to ensure strategic alignment and resource allocation.

• Emphasizes speed and quality of data generation as critical to development and partnership decisions.

DA-1726 (Obesity drug) development and differentiation

• DA-1726 is a dual GLP-1/glucagon agonist with a 3:1 activity ratio, aiming for optimal glycemic control and weight loss with minimal side effects.

• Early phase I data showed 9.1% weight loss and improved glycemic control in eight weeks at 48 mg, with moderate side effects prompting titration studies.

• Titration protocols (one-step and two-step) are designed to reduce side effects and improve patient comfort, with 16-week data expected by year-end.

• Notable reduction in waist circumference (about 10 cm in eight weeks) suggests significant visceral fat loss, to be further evaluated by MRI.

• Believes glucagon agonism will be a key component in next-generation obesity therapies, especially for patients with liver involvement.

DA-1241 (MASH drug) and combination strategies

• DA-1241 targets GPR119, stimulating natural GLP-1 production and hepatic effects, showing efficacy in glycemic control and ALT reduction in phase IIa.

• Combination studies with resmetirom and metformin demonstrated enhanced weight loss and glycemic control, with unique benefits over GLP-1 monotherapy.

• Combination with resmetirom led to 22% weight loss in preclinical models without reduced food intake, indicating a differentiated mechanism.

• Large potential market for MASH therapies, supported by high overlap with obesity and regulatory flexibility (no biopsy required for prescription).

• Preparing for an FDA meeting in the second half of the year to discuss phase II/III design, aiming for a biopsy-free path to late-stage trials.